Article Abstract:
Shire Pharmaceuticals has performed well since Rolf Stahel took over running the company in 1994. European Union authorities have approved the company's Alzheimer's treatment, Reminyl, which could gain a 20% stake in a market that is expanding. The company's Adderall attention deficit treatment is performing well, though Shire is still dependent on this drug for much of its profits, and does not have its own drug discovery. Shire has five proprietary drug-delivery techniques.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Shire Pharmaceuticals has a strong growth record through acquisitions, and the company's drug development strategy is low risk. There could be pressure on prices in US markets.
User Contributions:
Comment about this article or add new information about this topic:
Article Abstract:
Shire Pharmaceuticals plans a launch on the UK stock market in Feb 1996. The company is seeking to raise 20 million pounds sterling in order to develop new drugs. The company specializes in drugs for illnesses related to old age, and should benefit from the strong performance of the UK pharmaceutical industry. The company redevelops drugs which are then licensed, and also has a number of prescription drugs such as calcium supplements, a market segment where Shire accounts for 50% of the UK market.
User Contributions:
Comment about this article or add new information about this topic: